Literature DB >> 26235803

Estimation of total kidney volume in autosomal dominant polycystic kidney disease.

Edwin M Spithoven1, Maatje D A van Gastel1, A Lianne Messchendorp1, Niek F Casteleijn1, Joost P H Drenth2, Carlo A Gaillard1, Johan W de Fijter3, Esther Meijer1, Dorien J M Peters4, Peter Kappert5, Remco J Renken6, Folkert W Visser1, Jack F M Wetzels7, Robert Zietse8, Ron T Gansevoort9.   

Abstract

BACKGROUND: In autosomal dominant polycystic kidney disease (ADPKD), obtaining measured total kidney volume (mTKV) by magnetic resonance (MR) imaging and manual tracing is time consuming. Two alternative MR imaging methods have recently been proposed to estimate TKV (eTKVellipsoid and eTKVPANK), which require less time. STUDY
DESIGN: Cross-sectional and longitudinal diagnostic test study. SETTING & PARTICIPANTS: Patients with ADPKD with a wide range of kidney function and an approved T2-weighted MR image obtained at the University Medical Centers of Groningen, Leiden, Nijmegen, and Rotterdam, the Netherlands, in 2007 to 2014. Test set for assessing reproducibility, n=10; cohort for cross-sectional analyses, n=220; and cohort for longitudinal analyses, n=48. INDEX TESTS: Average times for eTKVellipsoid and eTKVPANK were 5 and 15 minutes, respectively. Bias is defined as (mTKV - eTKV)/mTKV × 100%; precision, as one standard deviation of bias. REFERENCE TESTS: mTKV using manual tracing to calculate the area within kidney boundaries times slice thickness. Average time for mTKV was 55 minutes.
RESULTS: In the test set, intra- and intercoefficients of variation for mTKV, eTKVellipsoid, and eTKVPANK were 1.8% and 2.3%, 3.9% and 6.3%, and 3.0% and 3.4%, respectively. In cross-sectional analysis, baseline mTKV, eTKVellipsoid, and eTKVPANK were 1.96 (IQR, 1.28-2.82), 1.93 (IQR, 1.25-2.82), and 1.81 (IQR, 1.17-2.62) L, respectively. In cross-sectional analysis, bias was 0.02% ± 3.2%, 1.4% ± 9.2%, and 4.6% ± 7.6% for repeat mTKV, eTKVellipsoid, and eTKVPANK, respectively. In longitudinal analysis, no significant differences were observed between percentage change in mTKV (16.7% ± 17.1%) and percentage change in eTKVellipsoid (19.3% ± 16.1%) and eTKVPANK (17.8% ± 16.1%) over 3 years. LIMITATIONS: Results for follow-up data should be interpreted with caution because of the limited number of patients.
CONCLUSIONS: Both methods for eTKV perform relatively well compared to mTKV and can detect change in TKV over time. Because eTKVellipsoid requires less time than eTKVPANK, we suggest that this method may be preferable in clinical care.
Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autosomal dominant polycystic kidney disease (ADPKD); PANK; ellipsoid; estimation methods; magnetic resonance imaging (MRI); total kidney volume (TKV); validation

Mesh:

Year:  2015        PMID: 26235803     DOI: 10.1053/j.ajkd.2015.06.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  21 in total

1.  3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease.

Authors:  Luc Breysem; Stéphanie De Rechter; Frederik De Keyzer; Maria Helena Smet; Bert Bammens; Maria Van Dyck; Maarten Hofmans; Raymond Oyen; Elena Levtchenko; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2018-01-06       Impact factor: 3.714

2.  Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.

Authors:  A Lianne Messchendorp; Edwin M Spithoven; Niek F Casteleijn; Wendy A Dam; Jacob van den Born; Wouter F Tonnis; Carlo A J M Gaillard; Esther Meijer
Journal:  BMC Nephrol       Date:  2018-12-19       Impact factor: 2.388

3.  Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Authors:  Ron T Gansevoort; Maatje D A van Gastel; Arlene B Chapman; Jaime D Blais; Frank S Czerwiec; Eiji Higashihara; Jennifer Lee; John Ouyang; Ronald D Perrone; Katrin Stade; Vicente E Torres; Olivier Devuyst
Journal:  Kidney Int       Date:  2019-03-09       Impact factor: 10.612

4.  Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Authors:  Esther Meijer; Folkert W Visser; Rene M M van Aerts; Charles J Blijdorp; Niek F Casteleijn; Hedwig M A D'Agnolo; Shosha E I Dekker; Joost P H Drenth; Johan W de Fijter; Maatje D A van Gastel; Tom J Gevers; Marten A Lantinga; Monique Losekoot; A Lianne Messchendorp; Myrte K Neijenhuis; Michelle J Pena; Dorien J M Peters; Mahdi Salih; Darius Soonawala; Edwin M Spithoven; Jack F Wetzels; Robert Zietse; Ron T Gansevoort
Journal:  JAMA       Date:  2018-11-20       Impact factor: 56.272

5.  Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease.

Authors:  Maatje D A van Gastel; Marie E Edwards; Vicente E Torres; Bradley J Erickson; Ron T Gansevoort; Timothy L Kline
Journal:  J Am Soc Nephrol       Date:  2019-07-03       Impact factor: 10.121

6.  Polycystic liver: automatic segmentation using deep learning on CT is faster and as accurate compared to manual segmentation.

Authors:  Bénédicte Cayot; Laurent Milot; Olivier Nempont; Anna S Vlachomitrou; Carole Langlois-Jacques; Jérôme Dumortier; Olivier Boillot; Karine Arnaud; Thijs R M Barten; Joost P H Drenth; Pierre-Jean Valette
Journal:  Eur Radiol       Date:  2022-02-10       Impact factor: 5.315

7.  Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images.

Authors:  Timothy L Kline; Marie E Edwards; Panagiotis Korfiatis; Zeynettin Akkus; Vicente E Torres; Bradley J Erickson
Journal:  AJR Am J Roentgenol       Date:  2016-06-24       Impact factor: 3.959

8.  Novel semi-automated kidney volume measurements in autosomal dominant polycystic kidney disease.

Authors:  Satoru Muto; Haruna Kawano; Shuji Isotani; Hisamitsu Ide; Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2017-11-03       Impact factor: 2.801

Review 9.  New treatment paradigms for ADPKD: moving towards precision medicine.

Authors:  Matthew B Lanktree; Arlene B Chapman
Journal:  Nat Rev Nephrol       Date:  2017-10-09       Impact factor: 28.314

Review 10.  Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice.

Authors:  Ron T Gansevoort; Mustafa Arici; Thomas Benzing; Henrik Birn; Giovambattista Capasso; Adrian Covic; Olivier Devuyst; Christiane Drechsler; Kai-Uwe Eckardt; Francesco Emma; Bertrand Knebelmann; Yannick Le Meur; Ziad A Massy; Albert C M Ong; Alberto Ortiz; Franz Schaefer; Roser Torra; Raymond Vanholder; Andrzej Więcek; Carmine Zoccali; Wim Van Biesen
Journal:  Nephrol Dial Transplant       Date:  2016-01-29       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.